Skip to main
OSTX
OSTX logo

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies Inc has demonstrated a robust outlook, particularly in the veterinary oncology market, which is projected to expand significantly from $1.58 billion in 2024 to $4.77 billion by 2034, indicating strong demand for its targeted immunotherapies. The company is advancing its OST-HER2 Phase 2b program, with encouraging two-year survival data and a favorable safety profile, suggesting potential for positive regulatory approval. Management's successful discussions with NYSE representatives and potential investors further solidify expectations for an enhanced market presence, driven by a coordinated operational strategy within the animal health sector.

Bears say

OS Therapies Inc reported a substantial net operating loss of $6.9 million for the third quarter of 2025, equating to a loss of $0.21 per share. This ongoing financial strain is attributed to the continued investment in its listeria-based cancer immunotherapy programs, specifically OST-HER2. The significant losses raise concerns about the company's financial sustainability and its ability to attract further investment or achieve profitability in the near term.

OSTX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 3 analysts, OSTX has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.